Kaijie Wu

3.3k total citations
117 papers, 2.5k citations indexed

About

Kaijie Wu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Kaijie Wu has authored 117 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Molecular Biology, 39 papers in Pulmonary and Respiratory Medicine and 36 papers in Oncology. Recurrent topics in Kaijie Wu's work include Bladder and Urothelial Cancer Treatments (24 papers), Prostate Cancer Treatment and Research (24 papers) and Urinary and Genital Oncology Studies (13 papers). Kaijie Wu is often cited by papers focused on Bladder and Urothelial Cancer Treatments (24 papers), Prostate Cancer Treatment and Research (24 papers) and Urinary and Genital Oncology Studies (13 papers). Kaijie Wu collaborates with scholars based in China, United States and Taiwan. Kaijie Wu's co-authors include Dalin He, Jinhai Fan, Xinyang Wang, Xinyang Wang, Jer‐Tsong Hsieh, Jin Zeng, Yule Chen, Jiancheng Zhou, Lei Li and Peng Guo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Kaijie Wu

114 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaijie Wu China 32 1.5k 657 653 652 311 117 2.5k
Liang Cheng China 30 1.4k 0.9× 763 1.2× 676 1.0× 355 0.5× 364 1.2× 80 2.5k
Akiko Kokubu Japan 25 2.2k 1.4× 649 1.0× 594 0.9× 404 0.6× 375 1.2× 29 3.0k
Elaine Kilgour United Kingdom 30 2.3k 1.5× 949 1.4× 677 1.0× 840 1.3× 426 1.4× 80 3.5k
Yanru Qin China 30 1.9k 1.2× 689 1.0× 1.1k 1.6× 454 0.7× 416 1.3× 98 2.7k
Dunfa Peng United States 32 1.7k 1.1× 689 1.0× 657 1.0× 491 0.8× 627 2.0× 87 2.6k
Jiujie Cui China 27 1.7k 1.1× 811 1.2× 857 1.3× 282 0.4× 197 0.6× 71 2.3k
Seema Sethi United States 33 1.9k 1.2× 957 1.5× 1.2k 1.9× 614 0.9× 271 0.9× 90 3.1k
Ming‐Tat Ling Hong Kong 29 1.6k 1.0× 798 1.2× 531 0.8× 384 0.6× 143 0.5× 51 2.5k
Eric Santoni‐Rugiu Denmark 35 1.7k 1.1× 1.2k 1.8× 681 1.0× 757 1.2× 524 1.7× 108 3.3k
Qingxia Fan China 30 1.4k 0.9× 717 1.1× 996 1.5× 486 0.7× 322 1.0× 111 2.3k

Countries citing papers authored by Kaijie Wu

Since Specialization
Citations

This map shows the geographic impact of Kaijie Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaijie Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaijie Wu more than expected).

Fields of papers citing papers by Kaijie Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaijie Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaijie Wu. The network helps show where Kaijie Wu may publish in the future.

Co-authorship network of co-authors of Kaijie Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Kaijie Wu. A scholar is included among the top collaborators of Kaijie Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaijie Wu. Kaijie Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wu, Wei, Hao Song, Yanan Gu, et al.. (2025). Carbon Dot Nanozymes with Ferrous Ion‐Chelating and Antioxidative Activity Inhibiting Ferroptosis to Alleviate Renal Ischemia‐Reperfusion Injury. Small. 21(16). e2407372–e2407372. 7 indexed citations
2.
Chen, Junru, Chenhao Xu, Qiang Wei, et al.. (2024). Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study.. Journal of Clinical Oncology. 42(16_suppl). TPS4625–TPS4625. 1 indexed citations
3.
Gu, Yanan, Shiqi Wu, Tianjie Liu, et al.. (2024). CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression. Cell Death and Disease. 15(1). 79–79. 29 indexed citations
4.
Gu, Yanan, et al.. (2023). Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer. Urologic Oncology Seminars and Original Investigations. 41(8). 354.e1–354.e9. 5 indexed citations
5.
6.
7.
Zhang, Dongxu, et al.. (2021). Development of embryos and larvae of Portunus trituberculatus (Decapoda, Brachyura) in off-season breeding mode. Crustaceana. 94(6). 679–695. 3 indexed citations
8.
Yun, Eun-Jin, Andrew Dang, Jiaming Guo, et al.. (2019). Downregulation of Human DAB2IP Gene Expression in Renal Cell Carcinoma Results in Resistance to Ionizing Radiation. Clinical Cancer Research. 25(14). 4542–4551. 22 indexed citations
9.
Xu, Xiaofeng, Kaijie Wu, Jinhai Fan, et al.. (2019). A Novel 450 nm Semiconductor Blue Laser System for Application in Colon Endoscopic Surgery: An Ex Vivo Study of Laser–Tissue Interactions. Photobiomodulation Photomedicine and Laser Surgery. 37(1). 25–30. 9 indexed citations
10.
Zhang, Zhichao, Yingfei Liu, Ke Wang, et al.. (2018). Activation of type 4 metabotropic glutamate receptor promotes cell apoptosis and inhibits proliferation in bladder cancer. Journal of Cellular Physiology. 234(3). 2741–2755. 21 indexed citations
11.
Guan, Bing, Kaijie Wu, Jin Zeng, et al.. (2016). Tumor-suppressive microRNA-218 inhibits tumor angiogenesis via targeting the mTOR component RICTOR in prostate cancer. Oncotarget. 8(5). 8162–8172. 55 indexed citations
12.
Xu, Shan, Zheng Yang, Yizeng Fan, et al.. (2016). Curcumin enhances temsirolimus-induced apoptosis in human renal carcinoma cells through upregulation of YAP/p53. Oncology Letters. 12(6). 4999–5006. 28 indexed citations
13.
Wang, Bin, Jun Huang, Jiancheng Zhou, et al.. (2016). DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein. Cellular Signalling. 28(11). 1623–1630. 19 indexed citations
14.
Zhou, Jiancheng, Tianlong Zhang, R C Pong, et al.. (2015). DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis. Cell Death and Disease. 6(10). e1955–e1955. 24 indexed citations
15.
Zhou, Jiancheng, Kaijie Wu, Guodong Zhu, et al.. (2014). Reciprocal Regulation of Hypoxia-Inducible Factor 2α and GLI1 Expression Associated With the Radioresistance of Renal Cell Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 90(4). 942–951. 34 indexed citations
16.
Wu, Kaijie, Daxing Xie, Yonglong Zou, et al.. (2013). The Mechanism of DAB2IP in Chemoresistance of Prostate Cancer Cells. Clinical Cancer Research. 19(17). 4740–4749. 55 indexed citations
17.
Wu, Kaijie, Jin Zeng, Jinhai Fan, et al.. (2013). Silibinin inhibits β-catenin/ZEB1 signaling and suppresses bladder cancer metastasis via dual-blocking epithelial–mesenchymal transition and stemness. Cellular Signalling. 25(12). 2625–2633. 98 indexed citations
18.
Zhang, Linlin, Min Jiao, Lei Li, et al.. (2012). Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. Journal of Cancer Research and Clinical Oncology. 138(4). 675–686. 70 indexed citations
19.
Zeng, Jin, Yi Sun, Kaijie Wu, et al.. (2011). Chemopreventive and Chemotherapeutic Effects of Intravesical Silibinin against Bladder Cancer by Acting on Mitochondria. Molecular Cancer Therapeutics. 10(1). 104–116. 63 indexed citations
20.
Zhang, Dong, Dalin He, Yan Xue, et al.. (2011). PrLZ Protects Prostate Cancer Cells from Apoptosis Induced by Androgen Deprivation via the Activation of Stat3/Bcl-2 Pathway. Cancer Research. 71(6). 2193–2202. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Liang Cheng Breakdown of academic impact, for papers by Akiko Kokubu Breakdown of academic impact, for papers by Elaine Kilgour Breakdown of academic impact, for papers by Yanru Qin Breakdown of academic impact, for papers by Dunfa Peng Breakdown of academic impact, for papers by Jiujie Cui Breakdown of academic impact, for papers by Seema Sethi Breakdown of academic impact, for papers by Ming‐Tat Ling Breakdown of academic impact, for papers by Eric Santoni‐Rugiu Breakdown of academic impact, for papers by Qingxia Fan
Rankless by CCL
2026